Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="279347"/>
<meta>
<versionId value="14"/>
<lastUpdated value="2024-11-16T19:33:35.200Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"/>
</meta>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper"/>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="CohortDefinition: T1DM-specific criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279347. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279347. Computable resource at: https://fevir.net/resources/Group/279347."/>
</valueRelatedArtifact>
</extension>
<url value="https://fevir.net/resources/Group/279347"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="urn:ietf:rfc:3986"/>
<value value="https://fevir.net/FOI/279347"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<title value="ConceptualCohortDefinition: T1DM-specific criteria"/>
<status value="active"/>
<publisher value="Computable Publishing LLC"/>
<contact>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</contact>
<description
value="i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria
ii. have been on the following daily insulin therapy for at least 1 year
..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)
iii. are between 18 and 64 years old at the time of informed consent
iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening"/>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<membership value="conceptual"/>
<combinationMethod value="all-of"/>
<characteristic>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="64572001"/>
<display value="Disease (disorder)"/>
</coding>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="46635009"/>
<display value="Diabetes mellitus type 1 (disorder)"/>
</coding>
</valueCodeableConcept>
<exclude value="false"/>
<description
value="Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria"/>
<method>
<text
value="based on the World Health Organization (WHO) diagnostic criteria"/>
</method>
</characteristic>
<characteristic>
<code>
<text value="Medication exposure"/>
</code>
<valueCodeableConcept>
<text
value="Insulin therapy with multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or continuous subcutaneous insulin infusion (CSII)"/>
</valueCodeableConcept>
<exclude value="false"/>
<description
value="Have been on the following daily insulin therapy for at least 1 year
..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)"/>
<durationDuration>
<value value="1"/>
<comparator value=">="/>
<unit value="years"/>
<system value="http://unitsofmeasure.org"/>
<code value="a"/>
</durationDuration>
</characteristic>
<characteristic>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="397669002"/>
<display value="Age"/>
</coding>
</code>
<valueRange>
<low>
<value value="18"/>
<unit value="years"/>
<system value="http://unitsofmeasure.org"/>
<code value="a"/>
</low>
<high>
<value value="64"/>
<unit value="years"/>
<system value="http://unitsofmeasure.org"/>
<code value="a"/>
</high>
</valueRange>
<exclude value="false"/>
<description
value="Are between 18 and 64 years old at the time of informed consent"/>
<timing>
<contextCode>
<coding>
<system value="http://snomed.info/sct"/>
<code value="182771004"/>
<display value="Informed consent for procedure"/>
</coding>
</contextCode>
<offsetDuration>
<value value="0"/>
</offsetDuration>
</timing>
</characteristic>
<characteristic>
<code>
<coding>
<system value="http://loinc.org"/>
<code value="39156-5"/>
<display value="Body mass index (BMI) [Ratio]"/>
</coding>
</code>
<valueRange>
<low>
<value value="18.5"/>
<unit value="kilogram per square meter (kg/m2)"/>
<system value="http://unitsofmeasure.org"/>
<code value="kg/m2"/>
</low>
<high>
<value value="30"/>
<unit value="kilogram per square meter (kg/m2)"/>
<system value="http://unitsofmeasure.org"/>
<code value="kg/m2"/>
</high>
</valueRange>
<exclude value="false"/>
<description
value="Have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening"/>
<timing>
<contextCode>
<text value="screening"/>
</contextCode>
<offsetDuration>
<value value="0"/>
</offsetDuration>
</timing>
</characteristic>
</Group>